To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer

Inclusion Criteria: * Age \>18, either sex * Histologically confirmed stage IV nasopharyngeal cancer * One bone metastasis at least confirmed by imaging * without chemotherapy or radiotherapy after bone metastasis * Life expectancy \> 6 M * ECOG \<= 2 * Adequate bone marrow reserve (WBC \> 3.5 x 109/L, Neutrophile \> 1.5 x 109/L, Platelet 100 x 109/L, Hb \> 90 g/L) * Serum creatinine\< 2.0 mg/dL (\< 1.5 times the upper limit of the normal range for the laboratory of the study center) * Signed ICF Exclusion Criteria: * Women who are pregnant or in lactation * Patients with hyperostosis * Systemic treatment for another cancer within the year prior to study entry * Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy * Initial serum creatinine \>265 micromol/L and/or progressive renal disease * Known hypersensitivity to any of the study drugs or to drugs with similar chemical structures * Use of investigational agents within 28 days of the Baseline visit, or participating simultaneously in any other clinical studies * Severe co-morbidity of any type that may interfere with assessment of the patient for the study